

EV 860818584 US

April 24, 2006


USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 

Sarah Barnett



PATENT

Customer No. 22,852

Attorney Docket No. 07579.0001-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)

Graham Edmund KELLY)

) Group Art Unit: 1623

Reissue Application No.: 09/602,191)

) Examiner: Patrick T. Lewis

U.S. Patent No.: 5,830,887)

) Confirmation No. 8264

Filed: June 22, 2000)

For: HEALTH SUPPLEMENTS)

CONTAINING PHYTO-)

OESTROGENS, ANALOGUES)

OR METABOLITES THEREOF)

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

NOTICE REGARDING RELATED LITIGATION

Applicant hereby notifies the U.S. Patent and Trademark Office of the status of five separate infringement lawsuits filed in the Southern District of New York, two of which are presently pending. The patents in suit, U.S. Patent No. 6,562,380 and 6,987,098, are related to the above-mentioned application.

STATUS OF RELATED LITIGATION

The first suit, *Novogen Research Pty. Ltd. v. Chattem, Inc.*, was filed on March 8, 2006. Both the U.S. 6,562,380 and U.S. 6,987,098 patents are involved in the litigation. Copies of the relevant documents are cited on the enclosed List of Related Litigation and Opposition Documents (Doc. Nos. 1 and 2) and submitted herewith. The litigation is currently pending.

The second suit, *Novogen Research Pty. Ltd. v. General Nutrition Centers, Inc.*, was filed May 12, 2004. U.S. 6,562,380 was the only patent involved in the litigation. A copy of the relevant documents are cited on the enclosed List of Related Litigation and Opposition Documents (Doc. Nos. 3 and 4) and submitted herewith. Novogen was granted a permanent injunction on January 7, 2005, and there is no appeal pending.

The third suit, *Novogen Research Pty. Ltd. v. Natural Alternatives, Intl.*, was filed February 10, 2005. U.S. 6,562,380 is the only patent involved in the litigation. A copy of the relevant documents are cited on the enclosed List of Related Litigation and Opposition Documents (Doc. Nos. 5 and 6) and submitted herewith. The litigation is currently pending.

The fourth suit, *Novogen Research Pty. Ltd. v. NBTY, Inc.*, was filed February 10, 2005. U.S. 6,562,380 was the only patent involved in the litigation. A copy of the relevant documents are cited on the enclosed List of Related Litigation and Opposition Documents (Doc. Nos. 7 and 8) and submitted herewith. A Stipulation of Dismissal by both parties was filed on January 6, 2006.

The fifth suit, *Novogen Research Pty. Ltd. v. Swanson Health Products, Inc.*, was filed February 19, 2004. Although no documents are available electronically from PACER, based on the timing of the lawsuit, it is believed that U.S. 6,562,380 was the only patent involved in the litigation. A copy of the relevant PACER docket report is cited on the enclosed List of Related Litigation and Opposition Documents (Doc. No. 9) and submitted herewith. The case was dismissed on April 12, 2004.

The related European patent prosecution, EP 0 656 786 B1, is presently in Opposition Proceedings before the EPO. Ten parties filed Notices of Opposition in June 2005. One party filed a Notice of Opposition in February 2006. The Opposition is currently pending. Copies of

the Notices and Exhibits are cited on the enclosed List of Related Litigation and Opposition Documents (Doc. Nos. 11-21) and submitted herewith.

EP 0 656 786 B1 is also involved in an infringement lawsuit in The Netherlands. Novogen filed suit against Care for Women B.V. on November 29, 2005. The lower court made a finding of non-infringement, and Novogen has appealed the decision. A copy of the translated documents filed in the EPO is cited on the enclosed List of Related Litigation and Opposition Documents (Doc. No. 10) and submitted herewith.

REMARKS


If there are any fees due in connection with the filing of this Notice not already accounted for, please charge the fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 24, 2006

By: Elisabeth Barek
Elisabeth Jaffe Barek
Reg. No. 46,797
Customer No. 22,852



LIST OF RELATED LITIGATION AND OPPOSITION DOCUMENTS

Doc. No.	DESCRIPTION
1	PACER Docket Report for Case No. 1:06-cv-01857-BSJ (<i>Novogen Research Pty. Ltd. v. Chattem</i>), dated April 4, 2006, 2 pages.
2	Complaint and Rule 7.1 Statement filed in Case No. 1:06-cv-01857-BSJ, dated March 8, 2006, 5 pages.
3	PACER Docket Report for Case No. 1:04-cv-03627-LTS-DFE (<i>Novogen Research Pty. Ltd. v. General Nutrition Centers, Inc.</i>), dated March 23, 2006, 4 pages.
4	Documents for Case No. 1:04-cv-03627-LTS-DFE: Complaint; Rule 7.1 Statement; First Amended Complaint; Answer, Affirmative Defenses, and Counterclaims to First Amended Complaint; Rule 7.1 Corporate Disclosure Statement; Preliminary Pre-trial Statement; Novogen Research Pty. Ltd.'s Reply to Defendant's Answer, Affirmative Defenses and Counterclaims; and Consent Judgment and Order of Permanent Injunction, 35 pages.
5	PACER Docket Report for Case No. 1:05-cv-01983-PKC (<i>Novogen Research Pty. Ltd. v. Natural Alternatives, Intl.</i>), dated March 23, 2006, 5 pages.
6	Documents for Case No. 1:05-cv-01983-PKC: Complaint; Rule 7.1 Statements; Answer, Counterclaims and Jury Demand; Civil Case Management Plan and Scheduling Order; Novogen Research Pty. Ltd.'s Reply to Defendant's Answer, Counterclaims and Jury Demand; Order of Dismissal; Letters from Novogen's Counsel to Judge regarding Settlement; Amended Civil Case Management Plan and Scheduling Order; and Order of Reference to a Magistrate Judge for Settlement, 26 pages.
7	PACER Docket Report for Case No. 1:05-cv-01984-PKC (<i>Novogen Research Pty. Ltd. v. NBTY, Inc.</i>), dated March 23, 2006, 5 pages.
8	Documents for Case No. 1:05-cv-01984-PKC: Complaint; Rule 7.1 Statements; Answer of NBTY, Inc.; Case Management Plan; Letter from NBTY's Counsel to Judge regarding Settlement; and Stipulation of Dismissal with Prejudice, 17 pages.
9	PACER Docket Report for Case No. 1:04-cv-01426-JSR (<i>Novogen Research Pty. Ltd. v. Swanson Health Products, Inc.</i>), dated March 23, 2006, 2 pages.
10	English Translations of Writ and the Decision of the District Court The Hague dated March 23, 2006, for Dutch Patent Infringement litigation brought by Novogen Research Pty. Ltd. against Care for Women B.V., 20 pages.
11	Notice of Opposition to EP 0 656 786 B1 by Care for Women B.V., filed February 24, 2006.
12	Notice of Opposition to EP 0 656 786 B1 by Laboratoires Arkopharma, filed June 20, 2005.
13	Notice of Opposition to EP 0 656 786 B1 by Strawman Ltd., filed June 16, 2005.
14	Notice of Opposition to EP 0 656 786 B1 by Jukunda Naturalzeneimittel, filed June 15, 2005.
15	Notice of Opposition to EP 0 656 786 B1 by Solbar Industries, Ltd., filed June 10, 2005.
16	Notice of Opposition to EP 0 656 786 B1 by Wolfgang Richter, filed June 15, 2005.
17	Notice of Opposition to EP 0 656 786 B1 by Alsitan GmbH & Co. KG, filed June 14, 2005.
18	Notice of Opposition to EP 0 656 786 B1 by Apomedica Pharmazeutische Produkte GmbH, filed June 14, 2005.
19	Notice of Opposition to EP 0 656 786 B1 by Gynea Laboratorios, S.L., filed June 14, 2005.
20	Notice of Opposition to EP 0 656 786 B1 by Zambon Group S.p.A., filed June 13, 2005.
21	Notice of Opposition to EP 0 656 786 B1 by Cognis Deutschland GmbH & Co. KG, filed June 17, 2005.